Clinical Relevance of Matrix Metalloproteinase 9 in Patients with Acute Coronary Syndrome

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 8, 2015, Pages 750-754

  Hamed, Gehan Mostafa ^a   Fattah, Mona Fathey Abdel ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

acute coronary syndrome; disease outcome; MMP 9

Indexed keywords

ENOXAPARIN; BIOLOGICAL MARKER; GELATINASE B; MMP9 PROTEIN, HUMAN;

ABDOMINAL CANCER; ABDOMINAL SURGERY; AGED; ARTICLE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEEP VEIN THROMBOSIS; ESOPHAGUS CANCER; EXTENDED PROPHYLAXIS; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; LENGTH OF STAY; LIVER CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PANCREAS CANCER; PATIENT COMPLIANCE; PATIENT EDUCATION; PELVIS CANCER; PELVIS SURGERY; PILOT STUDY; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; STOMACH CANCER; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; ACUTE CORONARY SYNDROME; BLOOD; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; STABLE ANGINA PECTORIS; SURVIVAL RATE;

ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; BIOMARKERS; DISEASE-FREE SURVIVAL; HUMANS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SURVIVAL RATE;

EID: 84939240602     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029614567309     Document Type: Article

References (32)

1. Govender R, De Greef J, Delport R, Becker PJ, Vermaak WJH,. Biological variation of ischemia modified albumin in healthy subjects. Cardiovasc J Afr. 2008; 19 (3): 141-144.
2. James WL, Patrick JS, kerrett MS, Gaziano JM,. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol. 2002; 5 (4): 1-6
3. Kumar A, Christopher PC,. Acute coronary syndromes: diagnosis and management, part I., Mayo Clin Proc. 2009; 84 (10): 917-938.
4. Tapson VF,. Acute pulmonary embolism. N Engl J Med. 2008; 358 (10): 1037-1052.
5. Hasdai D, Behar S, Boyko V, Bassand JP, Batter A,. Cardiac biomarkers and acute coronary syndromes-the Euro-Heart Survey of Acute Coronary Syndromes experience. Eur Heart J. 2003; 24 (13): 1189-1194.
6. Vink A, Pasterkamp G,. Atherosclerotic plaque burden, plaque vulnerability and arterial remodeling: the role of inflammation. Minerva Cardioangiol. 2002; 50 (2): 75-83.
7. Papazafirropoulou N, Tentolouris N,. Matrix metalloproteinases and cardiovascular diseases. Hippokratia. 2009; 13 (2): 76-82.
8. Borkakoti N,. Structural studies of matrix metalloproteinases. J Mol Med. 2000; 78 (5): 261-268.
9. Lehrke M, Greif M, Broedl UC, et al. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol. 2009; 8 (50): 50-59.
10. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R,. Concept of vulnerable/unstable plaque. Arterioscler Thrombo Vasc Biol. 2010; 30 (7): 1282-1292.
11. Newby AC,. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler ThrombVasc Biol. 2008; 28 (12): 2108-2114.
12. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006; 97 (2): 175-180.
13. Park JP, Lee BK, Shim M, et al. Relationship between multiple plasma biomarkers and vulnerable plaque determined by virtual histology intravascular ultrasound. Circ J. 2010; 74 (2): 332-336.
14. Kobayashi N, Hata N, Kume N, et al. matrix metalloproteinase-9 for the earliest stage acute coronary syndrome comparison with high-sensitivity troponin T. Circ J. 2011; 75 (12): 2853-2861.
15. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007; 115 (13): e356-e375.
16. Fox K, Garcia MA, Andissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of European Society of Cardiology. Eur Heart J. 2006; 27 (11): 1341-1381.
17. Vassiliadis E, Barascuk N, Didangelos A, Karsdal MA,. Novel cardiac-specific biomarkers and the cardiovascular continuum. Biomark Insights. 2012; 7: 45-57.
18. Tanindi A, Sahinarslan A, Elbeg S, Cemri M,. Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical presentation, extent and severity of atherosclerotic coronary artery disease. Open Cardiovasc Med J. 2011; 5 (1): 110-116.
19. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998; 32 (2): 368-372.
20. Guo C, Zhang S, Zhang J, et al. Correlation between the severity of coronary artery lesions and levels of estrogen, hs-CRP and MMP-9. Exp Ther Med. 2014; 7 (5): 1077-1180.
21. Nurkic J, Ljuca F, Nurkic M, Jahic E, Jahic M,. Biomarkers of plaque instability in acute coronary syndrome patients. Med Arh. 2010; 64 (2): 103-106.
22. Banach M, Markuszewski L, Zaslonka J, Grzegorckzyk J, Okonski P, Jegier B,. The role of inflammation in the pathogenesis of atherosclerosis. Przegl Epidimiol. 2004. 58 (4): 663-670.
23. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107 (7): 1579-1585.
24. Jonsson S, Lundberg A, Kälvegren H, Bergström I, Szymanowski A, Jonasson L,. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. PloS One. 2011; 6 (4): e19340.
25. Kelly D, Cockerill G, Ng LL, et al. Plasma matrix metalloproteinase-9 and left ventricular remodeling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J. 2007; 28 (6): 711-718.
26. Gostiljac D, Evi PB, Djuri D, et al. The importance of defining serum MMP-9 concentration in diabetics as an early marker of the rupture of atheromatous plaque in acute coronary syndrome. Acta Physiol Hung. 2011; 98 (1): 91-97.
27. Sundström J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures. The Framingham Heart Study. Circulation. 2004; 109 (23): 2850-2856.
28. Kannel WB, DAgostino RB, Silbershatz H, Sullivan L, Wilson PW, Levy D,. Profile for estimating risk of heart failure. Arch Intern Med. 1999; 159 (11): 1197-1204.
29. Kuach A, Bek J.D., Gogowska-Ligus J, Garczorz W, Sior Z.G., Effects of standard treatment on the dynamics of matrix metalloproteinases gene expression in patients with acute coronary syndromes. Pharmacol Rep. 2010; 62 (6): 1108-1116.
30. Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Stanley IP,. The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med. 2010; 153 (6): 387-395.
31. Arakaki PA, Marques MR, Santos MC,. MMP-1 polymorphism and its relationship to pathological processes. J Bio Sci. 2009; 34 (2): 313-320.
32. Wang KF, Huang P H, Chiang CH, et al. Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction. Coronary Artery Dis. 2013; 24 (1): 23-28.